Purpose To explore and compare the opinions of physicians, pharmacists and potential users on the readability of a package insert of an over-the-counter medicine. Methods Exploratory study based on the administration of a semi-open questionnaire. This instrument was developed according to the readability guideline of the European Medicine Agency (EMA) and used to evaluate participants' accessibility to, and comprehensibility of, the package insert for diclofenac 12.5 mg tablets. Sixty-three participants were recruited from the Lisbon region and enrolled in three groups: physicians (Dg), pharmacists (Pg) and potential consumers (PCg), with a minimum of 20 participants each. Results Almost all (85 %) of the 20 PCg participants were educated above the 9th grade, although the majority of them (95 %) referred to, at least, one package insert interpretation issue, mainly related to the comprehension of technical terms. Amongst other differences between the groups, the Pg participants (n = 22) obtained a significantly less favourable opinion regarding the layout of the titles. Furthermore, the Pg and Dg (n = 21) participants proposed technical enhancements, such as the use of a table to explain the posology, precautions in case of renal failure, or the recommendation to take the tablets with meals. Conclusions Differences in the way of using the diclofenac tablets are expected, considering the comprehension dissimilarities between health professionals and potential consumers. The package insert of diclofenac 12.5 mg could be enhanced for safer use. Regarding the readability assessment of this package insert, the method proposed in the EMA guidelines might not be as effective as expected. Future research is advisable.
Introduction
The labelling and package inserts (PIs) are components of medicinal products that must be developed regarding the clarity of information [1] . All medicine PIs approved in the European Union (EU) must be conceived in accordance with the directive 2004/27/EC (Article 59) to ensure the clarity of the PIs, therefore, contributing to the proper and safe use of medicinal products [2] . One of the missions of the European Medicines Agency (EMA) is the scientific evaluation of applications for EU marketing authorization, including the approval of the labelling and PIs of medicinal products. In addition, the EMA has developed legal requisites such as the "Guideline on the readability of the labelling and package leaflet of medicinal products for human use", with the intention of harmonizing the European procedures on this issue [1] .
With regards to the fact that medicines are one of the greatest current resources for the prevention and treatment of Electronic supplementary material The online version of this article (doi:10.1007/s00228-014-1645-6) contains supplementary material, which is available to authorized users. many diseases, access to safe and effective medicines is considered a basic human right [3, 4] . Self-medication is an important issue in the prevention and control of minor health problems, avoiding saturation of healthcare services, and is defined as the use in a responsible manner of non-prescription medicines (over-the-counter or OTC drugs), with the optional advice from a healthcare professional. Similarly to other medicinal products, OTC drugs are not hazard-free, with risks of interactions, drug abuse and poisoning associated with their use, which can be considered a public health problem [4, 5] . In Portugal, 2,914 pharmacies and 838 shops (other than pharmacies) are authorized to sell OTC drugs (2009 data) [6] . The sales of these drugs represent 16 % (in units) and 6 % (in value) of the global national market, with the group of analgesics and antipyretics (e.g., non-steroid antiinflammatory drugs or NSAIDs) representing the highest market share [7] .
Taking into account the relatively high sales of these medicines at a national level, the readability of the PIs of NSAIDs (particularly, OTC drugs) is an important issue. In this context, the aim of the present work was to explore and compare the opinions of physicians, pharmacists and potential users on the readability of a package insert of an OTC NSAID.
Methods
This was an exploratory study, based on the administration of a semi-open questionnaire ( Table 1 ) that was developed according to the readability guideline published by the European Commission (EC) [1] .
The PI of the diclofenac 12.5 mg tablets was selected due to the following reasons:
1) The recent approval of this medicine as an OTC in Portugal [6] ; 2) The high consumption of anti-inflammatory medicines in Portugal (26 % share of the total OTC market) [6] and; 3) The potential risk of arterial thromboembolic events associated with diclofenac intake, particularly if used in high doses. The Pharmacovigilance Risk Assessment Committee of EMA has recently confirmed the cardiovascular risk associated with diclofenac intake [8] .
Furthermore the last approval date of the PI of the diclofenac 12.5 mg tablets was February 2008, when the legibility proof of the package inserts was already a legal requirement [2] .
Following the EC guideline [1] , study participants were recruited using a convenient sampling strategy from the metropolitan Lisbon area (from March to December 2010). The participants were enrolled in three groups: physicians or doctors (Dg), pharmacists (Pg) and potential consumers (PCg), with a minimum of 20 participants each. The Dg, Pg and PCg participants were selected, respectively, from medical offices and clinics, community pharmacies, and shopping or residential areas.
Questionnaire
The questionnaire was structured in two parts ( Table 1) . The first part (PART A) comprised closed-ended questions based on a 5-point Likert rating scale (with 1 meaning strongly disagree). The participants used the rating scale to classify their opinion on the clarity, simplicity and comprehensibility of the text, and also on some typographic or printing issues.
The second part of the questionnaire (PART B) was composed of two semi-open questions about participants' opinions on each one of the six sections of the PI, namely: 1. What X is ( the name of the medicinal product) and what it is used for; 2. What you need to know before you < take > <use > X; 3. How to < take > <use > X; 4. Possible side effects; 5. How to store X; and 6. Package contents and other information [9] . In the first question, the participants were invited to describe text comprehension problems (question a), while in the second question the participants were asked to give suggestions on how to improve the clarity of the text (question b). All the study participants had unlimited time to consult the PI. An initial pilot test was performed to validate the appropriateness of the questionnaire [1] , using three patients, three physicians and three pharmacists. The questionnaire was selfadministered for health-care professionals, while for potential consumers an interview was used to increase response rates and avoid misinterpretations of the instructions. The interviews were conducted by a researcher pharmacist. No questionnaire usage issues were expressed by participants. All questionnaires responses were coded into a statistical database. To assure data entry accuracy, 10 % of the questionnaires were randomized and rechecked.
Statistical analyses
The data were analysed with the Statistical Package for the Social Sciences (SPSS v17). Descriptive statistics and nonparametric tests (Kruskal-Wallis test) were used, with a type I error level of p<0.05.
Results
Overall, the three groups enrolled 63 participants: 21 Dg, 22 Pg and 20 PCg. The percentage of female participants in each group was, respectively: 33 %, 64 %, and 60 %. Participants' age ranged between 22 and 71 years. The average age was, respectively: 45 (± 13.6 SD), 28 (±4.9 SD), and 26 (± 16.1 SD). Three (i.e. 15 %) of the PCg participants have not undertaken higher education studies. Physicians were mainly dentists (9 i.e. 43 %). All pharmacists worked at community pharmacies. The main results of the study are presented in the Appendix. Table 2 presents frequencies of relevant changes in PI sections for the three groups. Font size 2.
Font type 3.
The layout of the title of the sections 4.
Colour of the text 5.
Line spacing 6.
The use of the en-dash throughout the text 7.
Clarity of the text 8.
Length of the sentences 9.
Number of sentences in each paragraph 10. The description of the possible side effects 11. The comprehensibility of the medical terms 12. The clarity of the patients' instructions The majority of the participants expressed a favourable opinion on the graphical design of the PI (points 1 to 6 of The scores of the opinion questions about the length of the paragraphs, the description of the possible side effects, the patients' instructions, and the use of abbreviations throughout the text were not found statistically different between Pg, Dg and PCg. The majority of the participants presented a "neutral", "agree" or "strongly agree" opinion on these issues (Appendix). However, the scores on the clarity of the text (Kruskal-Wallis: Chi 2 =5.524; p=0.023), the comprehensibility of the medical terms (Kruskal-Wallis: Chi 2 = 15.972; p<0.001) and the repetition of the brand name of the medicine throughout the text (Kruskal-Wallis: Chi 2 =7.878; p=0.019) were statistically different between the three groups. The proportion of PCg participants that "strongly disagree" or "disagree" with the clarity of the text was significantly higher than the equivalent proportion of Dg or Pg participants (Appendix). PCg were more likely to prefer the repetition of the brand name throughout the text than pharmacists and physicians (60 %, 9.1 % and 4.8 %, respectively) (Appendix).
Questionnaire Part B: a) text not (or insufficiently) understood in each section of the PI Although no comprehension issues were mentioned by the healthcare professionals, almost all the PCg (95 %) mentioned at least one comprehension issue. In the majority of the cases these were associated with the high prevalence of difficult technical terms, such as non-steroidal anti-inflammatory drugs, dyspepsia, melena and hematemesis. Other issues mentioned were the way the possible side effects were described, and a high prevalence of long sentences in some paragraphs.
Questionnaire Part B: b) participants' suggestions to improve the clarity of the text in each section of the PI Participants from the three groups suggested at least one change in Section 2 of the PI (i.e., Before taking Diclofenac 12.5 mg). As expected, the number of suggestions made by PCg was less than the number made by Pg and Dg participants ( Table 2) .
In relation to the content of Section 3 (i.e., How to take Diclofenac 12.5 mg), both pharmacists and physicians suggested modifications, such as the simplification of the text, the utilization of a table to explain the posology, and an update of the information about not exceeding the maximum dosage. Pharmacists also referred to the absence of other relevant information, such as the recommendation to take the tablets with meals and precautions associated with renal failure. With regards to layout issues, both healthcare professionals and potential consumers suggested the use of various colours, underlining, bold font type and tables. None of the participants suggested the use of pictograms or warning signs.
Discussion
Medicines PIs are mandatory in most developed countries, but interestingly pharmaceutical regulations on the readability of PIs vary between countries. For instance, according to the regulations from the Food and Drug Administration (FDA), the use of a PI inside all packages of medicines is not mandatory in the United States of America, contrary to what happens in the EU [1, 10, 11] .
According to the EC legibility guideline [1] , it is recommended to enroll geriatric and low literacy patients in the PI legibility test, enhancing the chances of identifying readability issues. The average education of the PCg participants was higher than the average education of the Portuguese population, which presents 72 % educated below the 9th grade Table 2 Number of participants that made at least one suggestion on the improvement of the clarity of the text n Section 1 Section 2 Section 3 Section 4 Section5 Section 6 100 % n (%) n (%) n (%) n (%) n (%) n (%) PCg Potential consumers' group; Pg Pharmacists' group; Dg Doctors' group; Sections of the Package Insert: Section 1, What X is and what it is used for; Section 2, What you need to know before you < take > <use > X; Section 3, How to < take > <use > X; Section 4, Possible side effects; Section 5, How to store X; and S6, Package contents and other information i.e. the mandatory education in Portugal, and only 14 % attended a higher education course (2008 data) [12] . While this may be not considered an advantage to the design of the present study, since more interpretation issues would be expected if less educated PCg participants had been enrolled in the study, actually the present results suggest that more issues are expected on the proper use of medicines, assuming Portuguese patients in general present lower literacy and are usually less informed about health issues (e.g., asking fewer questions to practitioners). [13] [14] [15] . Some studies support the relevance of the design of PIs (e.g., manipulation of text colour within PIs sections) [16, 17] . Moreover, previous investigations demonstrated that the use of pictograms and warning signs in the PIs enhanced patients' comprehension [18] . Study participants did not consider the absence of figures in the PI unsatisfactory; consequently, consumers and health professionals enrolled in this study were not necessarily aware of the potential advantages of using illustrations, particularly in the case of PIs from selfmedication drugs.
The predictable cognitive differences between patients and healthcare professionals, about the content of the PI, were considered to be relevant. The mismatch in the interpretation of some medical lexicon adds further responsibility to healthcare professionals in assuring complete patient understanding. Medication errors have been associated with inadequate interpretation of the labelling or the PIs of medicinal products [19] [20] [21] [22] [23] [24] . In this context, healthcare professionals are responsible for assuring the transmission of information, fundamental to the adequate use of medicines, despite what materials might exist, in particular dosage instructions, side effects and strategies for patients' adherence [25] [26] [27] .
In another study [28] , the same PI (diclofenac 12.5 mg tablets) was optimized through the use of simple explanations of the technical terms within brackets, using the same legibility questionnaire and an equivalent number of participants. It was found that simple lexical modifications deeply improved the participants' comprehension of the PI. Therefore, the results of this study [28] constituted a measure of comparability with the results of the present investigation, since the PI of diclofenac 12.5 mg was significantly improved only through the addition of simple lexical equivalents.
Finally, professionals uncovered critical information gaps (e.g., not taking the medicine with meals and special care in case of renal impairment), which may possibly contribute to compromise the safe use of the medicine by patients.
Study Limitations
Study results cannot be extrapolated to the Portuguese population, since no sample representation was aimed for, following the EC guideline [1] . The PCg interviews should have been audio or video-recorded to allow for later indepth analysis. Ideally, the health outcomes resulting from diclofenac 12.5 mg PI legibility issues, as well as, the a priori expectations of each participant about the content of the PI, should have been assessed. Doctors' results should be interpreted with caution since most Dg participants were dentists, even if these physicians are heavy NSAIDs prescribers. Although the majority of the participants had a favourable opinion on the PI graphical design (e.g., font size, font type, dash use, etc.), the way in which these issues influenced participants' PI comprehension was also not specifically evaluated.
Conclusions
Although understandable discrepancies between potential consumers and health professionals are expected, the content of the diclofenac 12.5 mg PI might be improved in view of adequate usability for non-expert final users. In this PI, the use of technical terms was an issue for good comprehension, constituting a potential drug effectiveness issue and a risk regarding the safe use of this medicine. Written information given to patients would benefit from systematic contributions provided by local healthcare professionals.
Practice implications
Regarding the readability assessment of the diclofenac 12.5 mg tablets PI, the method proposed in the EMA readability guideline [1] , might not be as effective as expected. The present PI layout might benefit from adjustments to the type of medicine, i.e., a non-prescribed or self-medication drug. Additionally, it might be recommended to update the guideline, considering the enrolment of health professionals in PIs legibility tests. As well, there is a need to make critical assessments of the content of the PIs depending on the characteristic of the various populations (e.g., taking into account the different literacy rates amongst EU member states) [29] . Future research on this topic seems important as a way of assuring patients' safe and effective use of medicines. Contributions to the manuscript CP ─ contributed to the definition of the study design; developed the questionnaire and other necessary materials to support the study; managed the administration of the questionnaires; organized and performed the data treatment and drafted the first version of the article.
